Novel Therapies for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Friday, March 25, 2022, 8:00 AM - Saturday, March 25, 2023, 11:59 PM

AMA PRA Category 1 Credits™ (1.50 hours), AMA PRA Category 1 Credits™ Designated (1.50 hours)

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common and potentially debilitating condition in adults, impacting 13 million people in the U.S. The prevalence is 2-4 times more common in middle-aged adult males than females. CRSwNP is an essential clinical entity diagnosed based upon subjective and objective evidence of chronic sinonasal inflammation. The CRSwNP is frequently associated with asthma and allergic rhinitis, but the cellular and molecular mechanisms that contribute to the clinical symptoms are not fully understood.

There are no fees to participate in the activity. Participants must review all activity contents, including the learning objectives, disclosure statements, and post activity assessment to receive CME credit for participation.

Contact Information
Brian Waggoner, Program Manager
Medical Media Holdings, Inc.
[email protected]

1. Outline the pathophysiology of rhinosinusitis-associated nasal polyps and how to guide the selection of novel biologic therapy;
2. Accurately diagnose patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who may be eligible for treatment with biological therapy;
3. Evaluate emerging agents for CRSwNP based on their efficacy and safety data.

Physician Credit (ACCME/AMA)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Medical Media Holdings, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this webinar activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit (ANCC)
Amedco, a CME/CE company, and Medical Media Holding Inc. jointly sponsor this activity. Amedco is jointly accredited by the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medical Media Holding Inc, the medical education company, serves as a content and logistic provider for this activity.

Amedco designates this webinar for a maximum of 1.5 ANCC contact hours for nurses.

Nurse Practioners Credit
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Physician Assistant Credit
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours.

 

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Medical Director & Program Planners
The University of Cincinnati, Medical Media Holdings, Amedco, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Medical Media Holding, Inc.
Kamatham A. Naidu, PhD
Brian Waggoner

University of Cincinnati, Center for Continuous Professional Development
Susan P. Tyler, PhD, Associate Dean
Heather Muskopf, Program Manager
Robert V. Ellis, MD, Peer Reviewer

Amedco
Sheryl Morgan

Learner Assurance Statement
The University of Cincinnati is committed to mitigating all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with ineligible companies. The University of Cincinnati is committed to retaining only those speakers with financial interests that can be mitigated as they relate to the goals and educational integrity of the CME activity.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

John V Bosso, MD
Professor
Division of Rhinology
Department of Otorhinolaryngology, Head and Neck Surgery
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

The following faculty has reported relevant relationships with ineligible companies that have been mitigated:
Dr. Bosso discloses that he is on the advisory board for AstraZeneca, GlaxoSmithKline, Novartis, Optinose, and Regeneron; clinical research study P.I. for Cumberland

Michael E Wechsler, MD, MMSc
Director, The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

The following faculty has reported relevant relationships with ineligible companies that have been mitigated:
Dr. Wechsler discloses that he is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Equillium, Genentech, Genzyme, GlaxoSmithKline, Incyte, Kinaset, Novartis, Pulmatrix, Regeneron, Restorbio, Sanofi, Sound Biologics, Teva

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This activity is supported by an independent educational grant from GlaxoSmithKline.